Who Is Eligible for GLP-1 Weight Loss Medications?

Who Qualifies for GLP-1 Weight Loss Medications?

GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) have become some of the most sought-after weight loss treatments available. However, these are prescription medications, and not everyone is a candidate. Eligibility is determined by a combination of body mass index (BMI), medical history, and other health factors. Below, we outline the general criteria that healthcare providers typically consider when evaluating whether GLP-1 therapy may be appropriate for you.

BMI Requirements

The primary eligibility criterion for GLP-1 weight loss medications is BMI. In general, these medications may be prescribed for adults who meet one of the following thresholds:

• •A BMI of 30 or higher (classified as obesity)
• •A BMI of 27 or higher (classified as overweight) with at least one weight-related comorbidity, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea

BMI is not a perfect measure of health, and your provider may consider additional factors such as waist circumference, body composition, and overall metabolic health when making a determination. Some telehealth platforms use BMI as an initial screening tool during their intake process.

Age Requirements

Most GLP-1 medications for weight loss are approved for adults aged 18 and older. However, Wegovy (semaglutide 2.4 mg) has received FDA approval for use in adolescents aged 12 and older who meet the BMI criteria. Tirzepatide-based medications are currently approved only for adult use. Age requirements can vary by platform and prescribing provider, so it is important to confirm with your specific telehealth service.

Medical Conditions That May Qualify You

If your BMI falls between 27 and 30, you may still be eligible for GLP-1 therapy if you have one or more weight-related health conditions. Providers typically look for conditions such as:

• •Type 2 diabetes or prediabetes
• •Hypertension (high blood pressure)
• •Obstructive sleep apnea
• •High cholesterol or dyslipidemia
• •Cardiovascular disease risk factors
• •Non-alcoholic fatty liver disease

These conditions suggest that excess weight may be contributing to broader health risks, which can strengthen the clinical case for medication-assisted weight management.

Who Should NOT Take GLP-1 Medications

GLP-1 medications are not appropriate for everyone. There are certain medical conditions and circumstances that may make these medications unsafe. Your provider will screen for the following contraindications:

• •Pregnancy or plans to become pregnant (GLP-1 medications have not been studied in pregnant women and may pose risks to fetal development)
• •A personal or family history of medullary thyroid carcinoma (MTC)
• •A personal history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• •A history of pancreatitis, as GLP-1 medications may increase the risk of recurrence
• •Severe gastrointestinal conditions such as gastroparesis
• •Known hypersensitivity to semaglutide, tirzepatide, or any of the medication's inactive ingredients

The Online Consultation Process

Most telehealth platforms follow a similar process when evaluating your eligibility for GLP-1 medications. You will typically complete a health intake form that asks about your height, weight, medical history, current medications, and weight loss goals. A licensed provider then reviews your information and may follow up with additional questions via secure messaging or a video consultation. If the provider determines that you are a good candidate, they will prescribe the appropriate medication and have it shipped directly to you.

The entire process can often be completed within a few days, and many platforms offer ongoing support through regular check-ins with your provider to monitor progress and adjust dosing as needed.

Insurance vs. Cash Pay Options

Coverage for GLP-1 weight loss medications varies widely by insurance plan. Brand-name medications like Wegovy and Zepbound can cost over $1,000 per month without insurance, and many plans do not cover them for weight loss indications. Some patients may find success using manufacturer savings programs or prior authorization processes.

Many telehealth platforms offer compounded versions of semaglutide or tirzepatide at a significantly lower cash-pay price, typically ranging from $150 to $500 per month depending on the provider and dosage. These compounded formulations may be a more accessible option for patients who cannot obtain insurance coverage. It is important to choose a provider that uses a licensed 503B outsourcing facility for compounding to help ensure quality and safety.